COST EFFECTIVENESS OF EVEROLIMUS FOR SECOND LINE TREATMENT OF METASTATIC RENAL CELL CANCER IN SERBIA

被引：0
|
作者：
Mihajlovic, J. [1 ]
Pechlivanoglou, P. [1 ]
Sabo, A. [2 ]
Tomic, Z. [2 ]
Postma, M. J. [1 ]
机构：
[1] Univ Groningen, Groningen, Netherlands
[2] Univ Novi Sad, Fac Med, Novi Sad 21000, Serbia
来源：
VALUE IN HEALTH | 2012年 / 15卷 / 07期
关键词：
D O I：
10.1016/j.jval.2012.08.2141
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A427 / A427
页数：1
相关论文
共 50 条
  • [41] Second-line treatment of metastatic gastric cancer in the era of predictive biomarkers: A cost-effectiveness analysis.
    Lauren, Brianna
    Silver, Elisabeth
    Ingram, Myles
    Oh, Aaron
    Kumble, Lindsay
    Ostvar, Sassan
    Laszkowska, Monika
    Chu, Jacqueline N.
    Manji, Gulam Abbas
    Neugut, Alfred I.
    Hur, Chin
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [42] Recommendations for the treatment of patients with advanced or metastatic renal cell cancer with the combination of lenvatinib and everolimus
    Grande, E.
    Glen, H.
    Aller, J.
    Argenziano, G.
    Lamas, M. J.
    Ruszniewski, P.
    Zamorano, J. L.
    Edmonds, K.
    Sarker, S.
    Staehler, M.
    Larkin, J.
    ONKOUROLOGIYA, 2020, 16 (04): : 61 - 81
  • [43] Cost-effectiveness of second-line treatment with irinotecan or infusional 5-fluorouracil in metastatic colorectal cancer
    Levy-Piedbois, C
    Durand-Zaleski, I
    Juhel, H
    Schmitt, C
    Bellanger, A
    Piedbois, P
    ANNALS OF ONCOLOGY, 2000, 11 (02) : 157 - 161
  • [44] Cost-Effectiveness Analysis of Biomarker-Guided Treatment for Metastatic Gastric Cancer in the Second-Line Setting
    Lauren, Brianna
    Ostvar, Sassan
    Silver, Elisabeth
    Ingram, Myles
    Oh, Aaron
    Kumble, Lindsay
    Laszkowska, Monika
    Chu, Jacqueline N.
    Hershman, Dawn L.
    Manji, Gulam
    Neugut, Alfred I.
    Hur, Chin
    JOURNAL OF ONCOLOGY, 2020, 2020
  • [45] COST EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB FOR THE TREATMENT OF ADVANCED OR METASTATIC RENAL CELL CARCINOMA
    Yfantopoulos, N.
    Bafaloukos, L.
    Dimitriadis, I
    Skroumpelos, A.
    Karokis, A.
    VALUE IN HEALTH, 2022, 25 (12) : S184 - S185
  • [46] PHARMACOECONOMIC ANALYSIS OF THE USE OF EVEROLIMUS COMPARED TO AXITINIB IN SECOND LINE THERAPY OF PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
    Kolbin, A.
    Frolov, M.
    Kurylev, A.
    Balykina, Y.
    Proskurin, M.
    VALUE IN HEALTH, 2015, 18 (07) : A442 - A442
  • [47] Comparison of Axitinib and Everolimus in the Second Line Treatment of Metastatic Renal Cell Carcinoma Following Previous Treatment with a Tyrosine Kinase Inhibitor: a Multicentre Retrospective Analysis
    Iqbal, S.
    Badreldin, W.
    Sundar, S.
    Thompson, N.
    Tanguay, J.
    CLINICAL ONCOLOGY, 2016, 28 (05) : E15 - E16
  • [48] COST-EFFECTIVENESS ANALYSIS OF USING EVEROLIMUS OR AXITINIB IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA WHO HAVE FAILED TO USE OF PAZOPANIB OR SUNITINIB IN FIRST-LINE TREATMENT
    Romero Prada, M. E.
    Huerfano, L. M.
    Roa Cardenas, N. C.
    VALUE IN HEALTH, 2016, 19 (07) : A735 - A735
  • [49] Clinical analysis of everolimus in the treatment of metastatic renal cell carcinoma
    Ren, Zongtao
    Niu, Yunfeng
    Fan, Bo
    Wei, Shufei
    Ma, Yongliang
    Zhang, Xiaoyu
    Guo, Xiaoqiang
    Zhang, Aili
    ANNALS OF PALLIATIVE MEDICINE, 2021, 10 (01) : 584 - 589
  • [50] Sequential Treatment with Pazopanib and Everolimus in Metastatic Renal Cell Carcinoma
    Rossetti, Sabrina
    D'Aniello, Carmine
    Iovane, Gelsomina
    Scagliarini, Sarah
    Laterza, Maria M.
    De Vita, Fernando
    Savastano, Clementina
    Carteni, Giacomo
    Porricelli, Maria A.
    Berretta, Massimiliano
    Pisconti, Salvatore
    Facchini, Gaetano
    Cavaliere, Carla
    FRONTIERS IN PHARMACOLOGY, 2017, 8
12345